The Medical Letter website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more      
The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1498
Drugs for Depression
The full article is available to subscribers Subscriber Login   
Revised 3/5/18: The adverse effects sections of SSRIs, SNRIs, and tricyclic antidepressants have been revised to include information on QT interval prolongation.

Complete remission of symptoms is the goal of antidepressant therapy; partial response is associated with an increased risk of relapse. Improvement can occur within the first two weeks of drug therapy, but it may take 4-8 weeks to achieve a substantial benefit.1 Fewer than 50% of patients with depression respond to first-line pharmacotherapy, and the rate of response decreases with each subsequent drug trial.2 Following remission after a first episode of depression, many experts recommend continuing antidepressant treatment at the same dose for at least 6-12 months to consolidate recovery. For patients with recurrent depressive episodes, long-term maintenance therapy can reduce the risk of recurrence.

SSRIs – Selective serotonin reuptake inhibitors (SSRIs) are generally recommended for first-line treatment of major depression. There is no ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Drugs for Depression
Article code: 1498b
 Electronic, downloadable article - $25